Price
No data yet.
Social Signal Score
Revenue
$8.62M-2.61%Company Profile
- CEO
- Kevin L. Cornwell
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 146
- Beta
- 0.41
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 26.35
Financials
Revenue
$8.62M-2.6%Net Income
$2.79M+2.6%EBITDA
$3.65M-15.8%Free Cash Flow
$3.26M+791.8%EPS (diluted)
$0.88+22.2%Shares Outstanding (diluted)
3.18M-15.2%Operating Expenses
$2.04MCash & Debt
$85.20MReturn of Capital
$1.69MDividend per Share
$0.32Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $38.52M | $11.29M | $3.48 |
| 2024 | $40.90M | $13.87M | $3.96 |
| 2023 | $50.22M | $16.64M | $4.57 |
| 2022 | $52.28M | $16.47M | $4.53 |
| 2021 | $49.05M | $14.79M | $4.05 |
| 2020 | $42.18M | $10.80M | $2.95 |
| 2019 | $46.90M | $14.73M | $3.96 |
| 2018 | $42.00M | $18.55M | $4.97 |
| 2017 | $41.41M | $8.51M | $2.29 |
| 2016 | $39.30M | $12.13M | $3.22 |
| 2015 | $40.16M | $11.84M | $3.14 |
| 2014 | $41.28M | $11.38M | $3.02 |
| 2013 | $40.49M | $11.41M | $3.02 |
| 2012 | $41.55M | $10.17M | $2.74 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from UTMD's reported EPS growth of 1.9% a year over 13 years.
- EPS in 5 years
- $3.83
- Implied price
- $61.23
- Return from $70.96
- -2.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.44 — -57.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -8.1% | -17.3% | -14.7% | -12.4% | -10.3% | -8.4% |
| -3.1% | -12.8% | -10.1% | -7.7% | -5.5% | -3.5% |
| 1.9% | -8.3% | -5.5% | -2.9% | -0.6% | 1.5% |
| 6.9% | -3.8% | -0.8% | 1.9% | 4.3% | 6.5% |
| 11.9% | 0.7% | 3.8% | 6.6% | 9.2% | 11.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
93+16.67%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·9d ago·Neutral
Utah Medical Products: A $25 Million Buyback Isn't Enough Utah Medical Products maintains a Hold rating due to ongoing revenue declines and concerns over capital allocation despite recent actions. UTMD's Q3 2026 saw a 12.1% revenue decline but a 5.9% net income increase, driven by lower litigation and amortization expenses. Management deployed cash via a $25M share repurchase at $75/share and acquired Orion Medical Supplies, aiming to offset core business weakness.
View source ↗ - Newszacks.com·25d ago·Neutral
UTMD's Q3 Earnings Rise Y/Y on Lower Costs, Orion Acquisition Utah Medical's Q3 earnings per share rise 7% year over year despite a 12.1% revenue decline, aided by lower operating expenses. Management expects a smaller revenue decline for full-year 2026.
View source ↗ - Newsaccessnewswire.com·31d ago·Neutral
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 SALT LAKE CITY, UT / ACCESS Newswire / October 22, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2026 financial results that include changes from the prior year's same period results. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € o…
View source ↗ - Newszacks.com·45d ago·Positive
UTMD Trades at a Premium to the Industry: How to Play the Stock? Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
View source ↗ - Newsaccessnewswire.com·48d ago·Neutral
Utah Medical Products, Inc. Extends Tender Offer SALT LAKE CITY, UT / ACCESS Newswire / October 5, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The Offer was initially scheduled to expire at 5:00 p.m.
View source ↗ - Newsaccessnewswire.com·58d ago·Neutral
Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date SALT LAKE CITY, UT / ACCESS Newswire / September 25, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The conditions of the Offer are explained in detail in the SEC Form TO Offer to Purchase and Letter of Transmittal filed with the SEC at https://www.sec.gov/Archives/edgar/data/706698/000109690626001428/0001096906-26-001428-index.html The Offer …
View source ↗ - Newsaccessnewswire.com·59d ago·Negative
Utah Medical Products, Inc. Commences Tender Offer SALT LAKE CITY, UT / ACCESS Newswire / September 24, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The $75.00 per share price represents a 17% premium over the average daily closing price of the stock during the last twelve months, and a 21% premium over the average daily closing price of the stock during the last twenty-four months.
View source ↗
Earnings
Thu, Jan 28(in 2 months)
Estimates and results for UTMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by UTMD officers and directors.
- Bought
- $67k
- Sold
- $7.4m
1 trade
53 trades
- Cornwell Kevin Lbought
- Richins Paul Osold
- Richins Paul Osold
- Richins Paul Osold
- Richins Paul Osold
- Payne Barbara Asold
- Hoyer Ernst Gsold
- Hoyer Ernst Gsold
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in UTMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
